Insights on Health Care
1231 total results. Page 30 of 50.
Biosimilars Patent and Antitrust Perspectives Virtual Panel
Headlines that Matter for Companies and Executives in Regulated Industries
Twenty-five Arent Fox LLP practices have been recognized in the 2020 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.
Headlines that Matter for Companies and Executives in Regulated Industries
Headlines that Matter for Companies and Executives in Regulated Industries
In a decision very favorable to California hospitals and medical staffs, the Court of Appeal rejected a physician’s argument that he was denied due process during his peer review hearing because of hearing officer alleged bias.
The Federal Trade Commission issued a decision last week illustrating that even sophisticated executives need reminding that emails and texts will be “Exhibit A” of an antitrust violation.
Headlines that Matter for Companies and Executives in Regulated Industries
Headlines that Matter for Companies and Executives in Regulated Industries
Headlines that Matter for Companies and Executives in Regulated Industries
Late Friday, September 27, 2019, President Trump signed the Fair and Accurate Medicaid Pricing Act into law as part of the Continuing Appropriations Act.
The US District Court for the District of Columbia ruled that the Centers for Medicare & Medicaid Services (CMS) exceeded its statutory authority when it cut the Medicare payment rates for hospital services provided in the grandfathered off-campus provider-based department setting.
WASHINGTON — Arent Fox LLP is pleased to announce that Health Care Co-Leader Stephanie Trunk has once again been selected to the LMG Life Sciences Award List in the “Healthcare Pricing & Reimbursement” category.
On September 10, 2019, CMS ssued a final rule with comment period, titled Program Integrity Enhancements to the Provider Enrollment Process (the “Final Rule”), which enhances the government’s authority to deny or revoke health care providers from participating federal health care programs.
Headlines that Matter for Companies and Executives in Regulated Industries
FDA issued a Compliance Policy delaying enforcement of the DSCSA’s saleable returns verification requirement by one year. So now, instead of wholesale distributors having to comply by November 27, 2019, FDA will exercise enforcement discretion until November 27, 2020.
Headlines that Matter for Companies and Executives in Regulated Industries
In the latest fallout from a wide-ranging scandal, former USC gynecologist George Tyndall, who faces criminal charges for allegedly sexually abusing hundreds of students, has surrendered his medical license to the Medical Board of California.
We are pleased to provide you with the updated, 2019 version of the Arent Fox Survey of Data Breach Notification Statutes. The Arent Fox 2019 Survey serves as a reminder to the health care industry that HIPAA is only one of many data breach notification requirements. Make sure your breach response p
Please join Arent Fox in San Francisco for our annual Medical Staff Leaders and the Law Conference. This full day conference is designed to equip your medical staff team with the most current skills, tools, and information to navigate challenging issues and provide effective leadership.
Please join Arent Fox in Costa Mesa for our ninth annual Medical Staff Leaders and the Law Conference. This full day conference is designed to equip your medical staff team with the most current skills, tools, and information to navigate challenging issues and provide effective leadership.
Finance Partner Les Jacobowitz spoke with Banking New York after attorneys general in at least five states began conducting investigations tied to alleged manipulation of the London interbank offered rate (LIBOR), adding to probes by US and UK authorities.
Headlines that Matter for Companies and Executives in Regulated Industries
WASHINGTON — Fifty Arent Fox LLP attorneys have been rated as leaders in their profession by The Best Lawyers in America 2020.
In a Notice of Intent FDA reminded pharmaceutical manufacturers that if their drugs were not appropriately updated, certified or associated with a registered establishment, they will be marked “inactive” by FDA and the date of inactivation added to the listing record.